One Year Data Provide Evidence Of Effectiveness And Tolerability Of REPLAGALÂ® (agalsidase Alfa) In Fabry Patients
NYON, Switzerland, March 29, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented data that show favorable treatment effect and tolerability of REPLAGAL ® (agalsidase alfa) in Fabry patients who switched from Fabrazyme ® (agalsidase beta) or were naive to enzyme replacement therapy (ERT) after one year of treatment with REPLAGAL at the America College of Medical Genetics (ACMG) annual meeting in Charlotte, NC.
Fabry disease is a rare, X-linked, lysosomal storage disorder caused by insufficient activity of the alpha-galactosidase enzyme. As a result of this deficiency, patients experience a spectrum of signs and symptoms including impairment in renal and cardiac functions. The natural course of Fabry disease includes decrease of renal function and increase in left ventricular mass index (LVMI).
"It's common for Fabry patients to suffer from chronic kidney and cardiovascular disease; these are signs of disease progression," said Dr. Ozlem Goker-Alpan, Director at Lysosomal Disorders Research and Treatment Unit, Center for Clinical Trials, Fairfax, VA. "These interim results show the effectiveness and tolerability of REPLAGAL in Fabry patients after one year of treatment."Data Suggest Favorable Treatment Effect and Tolerability with REPLAGAL at the Recommended Dose of 0.2 mg/kg Body Weight after One Year of Treatment One year data from Shire's HGT-REP-059 multicenter, open-label treatment protocol, suggests that cardiac structure, as measured by LVMI, remained stable in treatment-naive and switch patients after one year of treatment with REPLAGAL. In treatment naive patients (n=22), mean LVMI was 48.5 g/m(2.7) at baseline and 50.7 g/m(2.7) at 12 months, an increase of 2.20 g/m(2.7) +/- 1.63; p=0.187. In switch patients (n=39), mean LVMI was 60.4 g/m(2.7) at baseline and remained virtually unchanged at 12 months at 60.3 g/m(2.7) (0.00 +/- 2.32; p=0.306). The small increases of LVMI observed in the study were not statistically significant and were below the progression expected from natural history data.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV